Key result
Global polio vaccination drives >99% drop in cases since 1988, nearing global eradication.
This review details how the Global Polio Eradication Initiative reduced global polio incidence by over 99% and outlines the strategic necessity of transitioning from trivalent to bivalent/monovalent OPV and IPV to achieve complete eradication of both wild-type and vaccine-derived polioviruses.
Answers are grounded in this paper and cite their sources.
Supports OPV-to-IPV transition planning in eradication programs; leaves open optimal immunogenicity solutions pending prospective data.
The global incidence of poliomyelitis has dropped by more than 99 per cent since the governments of the world committed to eradication in 1988. One of the three serotypes of wild poliovirus has been eradicated and the remaining two serotypes are limited to just a small number of endemic regions. However, the Global Polio Eradication Initiative (GPEI) has faced a number of challenges in eradicating the last 1 per cent of wild-virus transmission. The polio endgame has also been complicated by the recognition that vaccination with the oral poliovirus vaccine (OPV) must eventually cease because of the risk of outbreaks of vaccine-derived polioviruses. I describe the major challenges to wild poliovirus eradication, focusing on the poor immunogenicity of OPV in lower-income countries, the inherent limitations to the sensitivity and specificity of surveillance, the international spread of poliovirus and resulting outbreaks, and the potential significance of waning intestinal immunity induced by OPV. I then focus on the challenges to eradicating all polioviruses, the problem of vaccine-derived polioviruses and the risk of wild-type or vaccine-derived poliovirus re-emergence after the cessation of oral vaccination. I document the role of research in the GPEI's response to these challenges and ultimately the feasibility of achieving a world without poliomyelitis.
No takes yet. Share an insight, caveat, or question.
Nicholas C. Grassly (2013) conducted a review in Poliomyelitis. Oral poliovirus vaccine (OPV) and inactivated poliovirus vaccine (IPV) was evaluated on Global incidence and eradication of wild-type and vaccine-derived poliomyelitis. Global poliomyelitis incidence dropped by >99% since 1988 to 223 reported cases in 2012, though final eradication requires overcoming poor OPV immunogenicity and ceasing OPV to prevent VDPV outbreaks.
Synapse has enriched 10 related papers. Consider them for comparative context: